Furmonertinib Plus Radiotherapy for EGFR+ NSCLC With Pleural Effusion

This study is designed as a prospective, multi-center investigation to explore the efficacy and safety of furmonertinib combined with upfront thoracic radiotherapy with or without metastatic lesion radiotherapy in subjects with EGFR-mutant NSCLC and malignant pleural effusion (MPE), aiming to provide additional evidence-based medical support for optimizing the management of NSCLC-MPE subjects. In addition, peripheral blood ctDNA next-generation sequencing (NGS) will be performed at two time points-before the first furmonertinib treatment and one month after the completion of thoracic radiotherapy-to identify subpopulations most likely to benefit from this therapeutic approach and to elucidate resistance mechanisms specific to the radiotherapy-plus-furmonertinib combination, ultimately facilitating more personalized care for these subjects.

NCT Number	NCT07482605
Lead Sponsor	Jiangmen Central Hospital
Conditions	Lung Cancer (NSCLC), Malignant Pleural Effusions (Mpe)- Pleurodesis
Enrollment	63 participants
Start Date	2026-07-01
Primary Completion	2027-10-30 (estimated)
Study Completion	2028-01-01 (estimated)
Updated on ClinicalTrials.gov	2026-07-17